FDA Medical Device Development Tools (MDDT): Program & Qualified Tools Guide

Complete guide to the FDA Medical Device Development Tools (MDDT) program: 4 tool categories, 2-phase no-fee qualification process, and full matrix of all 21 qualified tools.

Direct Answer: What Is the FDA MDDT Program?

The FDA's Medical Device Development Tools (MDDT) program is a voluntary, no-fee regulatory qualification program operated by the Center for Devices and Radiological Health (CDRH). Under Section 507 of the Federal Food, Drug, and Cosmetic Act (FD&C Act, added by the 21st Century Cures Act of 2016), the MDDT program evaluates and formally qualifies methods, materials, or measurements used by medical device sponsors to assess device safety, effectiveness, or performance.

Once the FDA qualifies a tool for a specific Context of Use (COU), device sponsors can cite that qualified MDDT in Premarket Approval (PMA), 510(k), De Novo, or Humanitarian Device Exemption (HDE) submissions without having to re-validate the tool's scientific methodology or suitability.

Governing Statute: Section 507 of the FD&C Act (enacted under the 21st Century Cures Act of 2016).
Administering Authority: FDA Center for Devices and Radiological Health (CDRH), Office of Product Evaluation and Quality (OPEQ).
User Fee Requirement: Absolutely zero user fees ($0). Submitting an MDDT proposal or qualification package incurs no MDUFA user fee.
Total Qualified Tools to Date: 21 qualified tools listed in the official FDA registry as of February 10, 2026.
Four Qualification Categories: Clinical Outcome Assessments (COAs), Biomarker Tests, Non-clinical Assessment Models (NAMs), and a fourth "Other" bucket for tools that do not fit the first three.
Primary Administrative Deliverable: A public Summary of Evidence and Basis of Qualification (SEBQ) document published on the FDA website.
How Sponsors Cite a Qualified Tool: Citing the official MDDT Tracking Number on FDA CDRH Premarket Review Submission Cover Sheet (Form FDA 3514), Section F.

Key 2026 program updates:

Current Qualified Tally: As of the FDA MDDT program registry current February 10, 2026, 21 tools have received formal FDA qualification across 4 categories.
Latest 2026 Qualifications: The two newest additions are the Image Viewer Integrity Evaluation System (IVIES) (Digital Pathology Non-clinical Assessment Model, qualified February 3, 2026) and MolecuLightDX (Wound Care Bacterial Fluorescence Biomarker Test, qualified January 26, 2026).
Notable Wearable & Digital Tool: On May 1, 2024, FDA qualified the Apple Atrial Fibrillation History Feature as a Cardiology Biomarker Test, making it the first consumer wearable digital health feature qualified under MDDT to estimate AFib burden in clinical studies.
Qualification Process: Qualification involves a two-phase process (Proposal Phase then Qualification Phase) resulting in a public Summary of Evidence and Basis of Qualification (SEBQ).

For sponsors, citing a qualified MDDT reduces regulatory review cycles, eliminates redundant bench testing or study validation, and provides pre-agreed acceptance criteria during FDA pre-submission (Q-Sub) reviews.

What an MDDT Is and Why FDA Created the Qualification Program (Section 507 & 21st Century Cures)

Historically, medical device sponsors developing novel technology frequently faced regulatory uncertainty around measurement endpoints, bench-testing models, and patient questionnaires. A sponsor might spend years validating a custom animal model or patient survey for a pivotal trial, only for FDA reviewers to question the instrument's sensitivity, construct validity, or precision during 510(k) or PMA review.

Prior to the formal establishment of the MDDT program, if a medical device company created a novel computer simulation model to evaluate stent fatigue or developed a specialized patient questionnaire to measure quality of life following a surgical implant, that tool had to be justified from first principles in every single regulatory submission. If three different manufacturers used the exact same patient questionnaire in three separate PMA applications, FDA reviewers in different division branches were free to evaluate the questionnaire independently, sometimes reaching conflicting conclusions regarding its clinical validity or measurement reliability. This lack of centralized qualification created redundant validation testing, lengthened regulatory review times, and increased overall commercialization costs across the medical device industry.

To establish regulatory predictability, Congress enacted Section 507 of the FD&C Act under the 21st Century Cures Act (Public Law 114-255). Section 507 mandated that CDRH create a structured, transparent qualification framework for device development tools. Under Section 507, once the FDA evaluates the scientific evidence supporting a tool and issues a formal qualification determination for a defined Context of Use, that qualification holds binding regulatory weight across all CDRH review divisions.

What Is the "Context of Use" (COU)?

A central concept in the MDDT program is the Context of Use (COU). Qualification is not a blank-check approval for all applications. Instead, FDA qualifies a tool for a precisely defined boundary that specifies:

The target clinical population or device type (e.g., adult patients with NYHA Class II/III heart failure receiving interventional cardiac implants).
The specific measurement role (e.g., primary or secondary clinical endpoint for evaluating functional capacity or disease-specific health status).
The study design scope (e.g., pivotal randomized clinical trials, early feasibility studies, or benchtop MR safety testing).

If a sponsor uses a qualified MDDT within its exact COU, FDA reviewers are instructed to accept the tool's data without requesting further scientific justification for the tool itself. If a sponsor wishes to use a qualified tool outside its defined COU, the sponsor must submit supplemental validation data justifying the expanded application.

For broader context on how clinical study designs integrate validated assessment tools, see our guide to IDE clinical investigation for devices.

The Four MDDT Categories and How They Differ

CDRH categorizes MDDTs into four distinct functional categories based on the scientific nature of the assessment method:

1. Clinical Outcome Assessments (COAs)

COAs measure how a patient feels, functions, or survives in response to a medical intervention. COAs encompass four sub-types:

Patient-Reported Outcomes (PROs): Direct reports coming from the patient about their health status, symptoms, or functional limitations without interpretation by a clinician or caregiver. Examples of qualified MDDT PROs include the Kansas City Cardiomyopathy Questionnaire (KCCQ), Minnesota Living with Heart Failure Questionnaire (MLHFQ), BREAST-Q Reconstruction Module, FACE-Q Aesthetics, WOUND-Q, PROWL-SS (LASIK symptoms), AIOLIS (intraocular lens symptoms), and the INSPIRE Questionnaires for automated insulin dosing systems.
Observer-Reported Outcomes (ObsROs): Measurement based on an observation by a non-clinician caregiver (such as a parent or spouse) who observes the patient's daily functioning.
Clinician-Reported Outcomes (ClinROs): Standardized clinical evaluations conducted by a trained health professional using validated scoring scales.
Performance Outcomes (PerfOs): Measurements based on a patient performing a standardized task, such as a timed 6-minute walk test or a cognitive memory grid task.

For in-depth guidance on validating PRO instruments outside the MDDT pathway, consult our guide on patient-reported outcome instrument validation for device trials.

2. Biomarker Tests

Biomarker tests measure a biological, physiological, or anatomical characteristic objectively as an indicator of pathogenic processes, toxicological response, or clinical response to a device intervention. Biomarker tools can include molecular assays, digital sensor algorithms, or quantitative imaging measures.

Examples of Qualified Biomarker MDDTs: the Apple Atrial Fibrillation History Feature for estimating AFib burden (Cardiology / Patient Monitoring), MolecuLightDX for real-time bacterial fluorescence imaging in wound care, and the OSIRIX CDE Software Module as a neuro-imaging biomarker for multiple sclerosis clinical trials.

3. Non-clinical Assessment Models (NAMs)

NAMs replace, reduce, or refine animal or clinical testing through benchtop engineering models, computational simulations, in vitro tissue assays, or mathematical algorithms. NAMs are rapidly gaining prominence under FDA's broader push for New Approach Methodologies.

Examples of Qualified NAM MDDTs: the Rubric for Applying CVSS to Medical Devices (a cybersecurity vulnerability-scoring model), Virtual MRI Safety Evaluations of Medical Devices, the CHRIS Chemical Risk Calculator for color-additive biocompatibility, an Accelerated Testing model for long-term material biostability, the ENDPOINT numaScrew Virtual Pullout Test for orthopedic and dental implants, and the Image Viewer Integrity Evaluation System (IVIES) for digital pathology displays.

4. Other

A fourth bucket for tools that do not fit the first three categories. The single qualified "Other" MDDT to date is the UCSF Lethal Arrhythmia Database (LAD), a reference ECG dataset for evaluating the arrhythmia-detection algorithms of Cardiology and Patient Monitoring devices.

In-Depth Profiles of Featured Qualified MDDT Tools

To illustrate the practical regulatory impact of the MDDT program, the following detailed profiles examine several of the most widely cited qualified tools across digital health, cardiology, surgery, and non-clinical testing:

1. Apple Atrial Fibrillation History Feature (Biomarker Test, Qualified May 1, 2024)

FDA Reference: Qualified Cardiology / Patient Monitoring Biomarker Test; full details in the FDA SEBQ.
Context of Use: Qualified as a digital health biomarker test for use in clinical studies evaluating medical devices designed to treat or prevent atrial fibrillation (such as cardiac ablation catheters or left atrial appendage closure devices). The feature uses photoplethysmography (PPG) sensors on the Apple Watch to analyze pulse rate data and estimate weekly AFib burden (the percentage of time a patient's heart is in AFib).
Regulatory Impact: Prior to qualification, cardiac device trials required patients to wear cumbersome Holter monitors or implantable loop recorders (ILRs) to track AFib recurrence. By qualifying the Apple AFib History Feature, FDA established a non-invasive, consumer-wearable biomarker endpoint that sponsors can integrate into clinical trials, lowering patient burden and reducing study monitoring costs.

2. MolecuLightDX Bacterial Imaging Assay (Biomarker Test, Qualified Jan 26, 2026)

FDA Reference: Qualified Wound Care and Plastic Surgery Biomarker Test; full details in the FDA SEBQ.
Context of Use: Qualified for use in clinical trials evaluating wound-care medical devices, advanced wound dressings, and tissue regeneration matrices. MolecuLightDX is a handheld point-of-care fluorescence imaging device that detects clinically significant bacterial loads (such as Staphylococcus aureus and Pseudomonas aeruginosa) in real time by capturing endogenously produced bacterial porphyrins and pyoverdine.
Regulatory Impact: Provides an objective, real-time biomarker for quantifying bacterial burden at the wound bed, replacing subjective clinical assessment or delayed swab culture results during clinical evaluation of antimicrobial dressings and debridement tools.

3. Image Viewer Integrity Evaluation System / IVIES (NAM, Qualified Feb 3, 2026)

FDA Reference: Qualified Digital Pathology Non-clinical Assessment Model; full details in the FDA SEBQ.
Context of Use: Qualified as a non-clinical assessment model for evaluating digital pathology image displays, whole slide imaging (WSI) software, and medical diagnostic monitors. IVIES evaluates image compression algorithms, display luminance fidelity, and pixel degradation to ensure digital pathology images preserve diagnostic integrity.
Regulatory Impact: Allows digital pathology and AI diagnostic software developers to validate viewer software and compression algorithms using a pre-qualified benchtop framework without conducting costly reader-study clinical trials for every software update.

4. Kansas City Cardiomyopathy Questionnaire / KCCQ (COA, Qualified Oct 19, 2017)

FDA Reference: Qualified Cardiology Clinical Outcome Assessment; full details in the FDA SEBQ.
Context of Use: Qualified as a patient-reported outcome instrument for measuring health status, physical limitations, symptom frequency, social limitations, and quality of life in adult heart failure patients (NYHA Class II-IV) enrolled in clinical trials for cardiovascular devices (such as ventricular assist devices, transcatheter valve repair systems, and remote hemodynamic monitors).
Regulatory Impact: As the first tool qualified under the MDDT program, the KCCQ established the gold standard for clinical outcome assessment in cardiovascular device PMA trials, enabling sponsors to use KCCQ score improvements as primary or co-primary efficacy endpoints.

Complete Matrix: All 21 FDA-Qualified MDDTs Today

The following reference table lists all 21 qualified Medical Device Development Tools in the official FDA registry as of February 10, 2026 (the "Content current as of" date on the FDA page), in chronological qualification order:

Kansas City Cardiomyopathy Questionnaire (KCCQ). Product Area: Cardiology. Category: Clinical Outcome Assessment. Qualified: Oct 19, 2017.
Minnesota Living with Heart Failure Questionnaire (MLHFQ). Product Area: Cardiology. Category: Clinical Outcome Assessment. Qualified: Mar 19, 2018.
OSIRIX CDE Software Module. Product Area: Neurology. Category: Biomarker Test. Qualified: Mar 12, 2019.
Tissue Mimicking Material (TMM) for Preclinical Acoustic Performance Characterization of High Intensity Therapeutic Ultrasound (HITU) Devices. Product Area: Imaging. Category: Non-clinical Assessment Model. Qualified: Jul 10, 2019.
INSPIRE Questionnaires (Insulin Dosing Systems: Perceptions, Ideas, Reflections, and Expectations). Product Area: Automated Insulin Dosing (AID). Category: Clinical Outcome Assessment. Qualified: Jun 24, 2020.
BREAST-Q Reconstruction Module. Product Area: Plastic Surgery. Category: Clinical Outcome Assessment. Qualified: Aug 20, 2020.
Rubric for Applying CVSS to Medical Devices. Product Area: Cybersecurity. Category: Non-clinical Assessment Model. Qualified: Oct 20, 2020.
IMAnalytics with MRIxViP1.5T/3.0T And BCLib. Product Area: Active Implanted Medical Devices (AIMDs). Category: Non-clinical Assessment Model. Qualified: May 20, 2021.
Patient-Reported Outcomes with LASIK Symptoms and Satisfaction (PROWL-SS). Product Area: Ophthalmology. Category: Clinical Outcome Assessment. Qualified: Jun 17, 2021.
Virtual MRI Safety Evaluations of Medical Devices. Product Area: Imaging. Category: Non-clinical Assessment Model. Qualified: Nov 16, 2021.
FACE-Q | Aesthetics. Product Area: Plastic Surgery, Dermatology. Category: Clinical Outcome Assessment. Qualified: Apr 26, 2022.
CHemical RISk Calculator (CHRIS) – Color Additives. Product Area: Toxicology, Biocompatibility. Category: Non-clinical Assessment Model. Qualified: Nov 28, 2022.
Anatomical Female CAD Model + Ansys HFSS/Mechanical FEM for Temperature Rise near an Orthopedic Femoral Nail Implant during a 1.5 T MRI Scan. Product Area: Orthopedic, MR Safety Labeling. Category: Non-clinical Assessment Model. Qualified: Mar 30, 2023.
Accelerated Testing to Prove Long-Term Material Biostability. Product Area: Biostability. Category: Non-clinical Assessment Model. Qualified: Aug 9, 2023.
UCSF Lethal Arrhythmia Database (LAD). Product Area: Cardiology, Patient Monitoring. Category: Other. Qualified: Mar 28, 2024.
Apple Atrial Fibrillation History Feature. Product Area: Cardiology, Patient Monitoring. Category: Biomarker Test. Qualified: May 1, 2024.
Assessment of IntraOcular Lens Implant Symptoms (AIOLIS) instrument. Product Area: Ophthalmology. Category: Clinical Outcome Assessment. Qualified: May 16, 2024.
WOUND-Q. Product Area: Plastic Surgery, Wound Care, Dermatology. Category: Clinical Outcome Assessment. Qualified: Nov 8, 2024.
ENDPOINT numaScrew Virtual Pullout Test. Product Area: Orthopedic, Dental. Category: Non-clinical Assessment Model. Qualified: Apr 10, 2025.
MolecuLightDX. Product Area: Wound Care and Plastic Surgery. Category: Biomarker Test. Qualified: Jan 26, 2026.
Image Viewer Integrity Evaluation System (IVIES). Product Area: Digital Pathology. Category: Non-clinical Assessment Model. Qualified: Feb 3, 2026.

Comparing MDDTs with Recognized Consensus Standards and CDER DDTs

It is important for regulatory leads to distinguish the MDDT program from other FDA regulatory pathways and international standardization frameworks:

MDDT vs. Recognized Consensus Standards (e.g., ISO, ASTM, IEEE)

Recognized consensus standards (such as ISO 10993 for biocompatibility or IEC 60601 for electrical safety) define broad technical requirements and testing specifications developed by voluntary standards organizations. In contrast, an MDDT is a specific, turn-key measurement instrument, software algorithm, patient questionnaire, or benchtop model qualified by CDRH for a precise Context of Use. While a consensus standard tells you what principles to test, an MDDT provides a pre-validated tool that yields pre-agreed scientific evidence.

MDDT (CDRH) vs. Drug Development Tool / DDT (CDER)

The MDDT program is operated exclusively by CDRH for medical devices. The CDER Drug Development Tool (DDT) qualification program operates under separate guidance for pharmaceuticals and biologics (covering animal models, biomarker qualification, and COAs for drug trials). While both programs share a two-phase qualification structure under Section 507 of the FD&C Act, MDDT includes non-clinical engineering assessment models (such as FEA fatigue models and CFD fluid dynamics) unique to device engineering, which do not exist under CDER's DDT framework.

The Two-Phase Qualification Process: Proposal Phase to Qualification Phase

Submitting a tool for MDDT qualification is a voluntary, non-interactive administrative process with zero user fees.

Phase 1: The Proposal Phase

In the Proposal Phase, the tool developer submits an MDDT Proposal Package to CDRH. The proposal must contain:

Tool Description: Detailed explanation of the tool's design, operational mechanics, and measurement outputs.
Proposed Context of Use (COU): Clear boundary statement specifying the target device types, patient populations, and study measurement role.
Qualification Plan: Outline of the validation testing, clinical studies, or benchtop data the developer plans to collect to demonstrate that the tool is reliable, reproducible, and scientifically valid within the proposed COU.

Upon receipt of the Proposal Package, CDRH conducts an interdisciplinary review and can provide feedback on the plan before issuing a determination accepting the proposal into the MDDT program, requesting plan modifications, or declining qualification.

Phase 2: The Qualification Phase

Once FDA accepts the Proposal Package, the developer executes the Qualification Plan and compiles the full validation dataset into a full Qualification Package. FDA then reviews the evidence package for the qualification decision. Upon successful review, CDRH issues a formal qualification determination and publishes the Summary of Evidence and Basis of Qualification (SEBQ) on the public FDA website.

Deliverable: The Summary of Evidence & Basis of Qualification (SEBQ)

Upon successful qualification, CDRH publishes a public Summary of Evidence and Basis of Qualification (SEBQ) on the FDA MDDT website. The SEBQ serves as the authoritative public record, containing:

The exact Context of Use (COU) statement.
Summary of validation data supporting reliability, precision, and clinical relevance.
Instructions for device sponsors on how to cite and implement the tool in regulatory submissions.

How to Use a Qualified MDDT in a Submission (Form 3514 & Cover Letter)

Citing an existing qualified MDDT in a 510(k), PMA, De Novo, or IDE submission is straightforward and requires no separate user fee or prior FDA approval.

Step-by-Step Execution Workflow:

Verify Context of Use Alignment: Carefully inspect the public SEBQ document for the target MDDT. Confirm that your clinical study population, device indication, and measurement role fall strictly within the qualified COU boundary.
Obtain the MDDT Submission Number: Locate the MDDT submission number printed on the tool's SEBQ on the FDA website (each SEBQ carries its own submission reference).
Complete Form FDA 3514 (Section F): On the CDRH Premarket Review Submission Cover Sheet (Form FDA 3514), navigate to Section F: Medical Device Development Tools (MDDT). Check the "YES" box, insert the MDDT Tracking Number, and provide the tool name.
Include COU Affirmation in Cover Letter: In your submission cover letter, include an explicit affirmation statement confirming that the qualified tool was implemented without modification according to its SEBQ instructions.
Attach Study Results: Attach the testing data generated using the qualified tool protocol. Because the tool itself is pre-qualified, FDA reviewers will skip tool methodology review and proceed directly to evaluating your device performance data.

For sponsors incorporating real-world data alongside qualified biomarkers, review our guide to real-world evidence for medical devices.

Should You Pursue or Cite an MDDT? Decision Framework for Sponsors

Deciding whether to reuse an existing qualified MDDT versus submitting a new tool for qualification depends on your commercial strategy and pipeline reuse potential.

Scenario 1: Reusing an Existing Qualified Tool (Recommended for Most Sponsors)

If your target endpoint or bench testing model is already covered by one of the 21 qualified MDDTs, reusing the qualified tool is the most efficient path. Citing an existing tool requires zero extra FDA review fees, eliminates tool validation risks, and provides instant reviewer acceptance during 510(k) or PMA review.

Scenario 2: Submitting a New Tool for MDDT Qualification (For Tool Developers & Platform Companies)

Pursuing formal MDDT qualification for a new tool requires a significant investment of time (typically 12 to 24 months to complete Phase 1 and Phase 2 reviews) and validation testing. Seeking qualification makes strategic sense if:

You are a specialized medical software, digital health, or contract testing vendor seeking to establish your tool as the industry-standard benchmark.
You are a device manufacturer developing a proprietary platform technology or novel biomarker that you intend to reuse across multiple internal pipeline products over the next decade.

Scenario 3: In-House Validation Without Seeking MDDT Qualification

If you develop a novel bench model or custom patient survey that will be used in only a single, one-off 510(k) or PMA submission, pursuing formal MDDT qualification is usually unnecessary. Instead, validate the tool within your single submission package using standard Q-Submission feedback.

For sponsors developing early-stage novel technology, evaluate how MDDT qualification aligns with the FDA Early Feasibility Studies program.

Frequently Asked Questions (FAQs)

Is there a fee to submit an MDDT for qualification?

No. The FDA MDDT program is a voluntary program with zero user fees ($0). Unlike MDUFA user fees required for 510(k) or PMA submissions, CDRH does not charge developers for submitting MDDT proposals or qualification packages.

Can a qualified MDDT be used outside device development, for clinical diagnosis or treatment?

No. Qualification of an MDDT by FDA applies solely to its use in medical device development studies and regulatory submissions. Qualification does not constitute clinical clearance, approval, or diagnostic authorization for patient care outside of a device study context.

What is the difference between an MDDT and the FDA Drug Development Tool (DDT) program?

The MDDT program is administered by CDRH specifically for medical devices. The Drug Development Tool (DDT) program is administered by CDER for pharmaceuticals and biological products. While both share the concept of context-of-use qualification, MDDT encompasses benchtop engineering models (FEA/CFD) and hardware/software tools unique to device technology.

Which MDDTs already exist for cardiovascular, ophthalmology, and wound-care devices?

Cardiovascular: KCCQ and MLHFQ (heart-failure clinical outcome assessments), the UCSF Lethal Arrhythmia Database (an "Other" reference ECG dataset for arrhythmia-detection algorithms), and the Apple Atrial Fibrillation History Feature (an AFib-burden biomarker test).
Ophthalmology: PROWL-SS (LASIK symptoms and satisfaction) and AIOLIS (intraocular lens implant symptoms), both clinical outcome assessments.
Wound Care: WOUND-Q (a clinical outcome assessment) and MolecuLightDX (a bacterial-fluorescence biomarker test).

Sources & Regulatory References

FDA MDDT Main Program Page: FDA Medical Device Development Tools (MDDT) - Official registry of all 21 qualified tools, SEBQ links, and submission instructions.
FDA MDDT Qualification Guidance: Qualification of Medical Device Development Tools Guidance - Authoritative guidance document (Docket FDA-2016-D-2986).
FDA Proposal Submission Content: MDDT Proposal Submission Content Guidance - Details on Phase 1 proposal requirements.
21st Century Cures Act: Public Law 114-255 Section 507 - Statutory authorization for the MDDT program.
MolecuLightDX MDDT Announcement: MolecuLightDX FDA Qualification Notice - Official press announcement for the January 2026 qualification.